1. Treanor JJ, Falsey A: Respiratory viral infections in the elderly. Antiviral
Research 1999, 44:79-102.
2. Webster RG: Immunity to influenza in the elderly. Vaccine 2000,
18:1686-1689.
3. Falsey A, Dallal G, Formica M, Andolina G, Hamer D, Leka L, Meydani S:
Long-term care facilities: A cornucopia of viral pathogens. Journal of the
American Geriatrics Society 2008, 56:1281-1285.
4. Yoshikawa TT, Norman DC: Infectious disease in the aging Towota, NJ:
Humana Press; 2000.
5. Canaday D, Amponsah N, Jones L, Tisch D, Hornick T, Ramachandra L:
Influenza-induced production of interferon-α is defective in geriatric
individuals. Journal of Clinical Immunology 2010, 30:373-383.
6. Fujihashi K, Koga T, McGhee JR: Mucosal vaccination and immune
responses in the elderly. Vaccine 2000, 18:1675-1680.
7. Fulop T, Pawelec G, Castle S, Loeb M: Immunosenescence and vaccination
in nursing home residents. Clinical Infectious Diseases 2009, 48:443-448.
8. Huang YP, Pechere JC, Michel M, Gauthey L, Loreto M, Curran JA, Michel JP:
In vivo T cell activation, in vitro defective IL-2 secretion, and response to
influenza vaccination in elderly women. Journal of Immunology 1992,
148:715-722.
9. Joshi SR, Shaw AC, Quagliarello VJ: Pandemic influenza H1N1 2009, innate
immunity, and the impact of immunosenescence on influenza vaccine.
Yale Journal of Biology and Medicine 2009, 82:143-151.
10. Kovaiou RD, Grubeck-Loebenstein B: Age-associated changes within CD4+
T cells. Immunology Letters 2006, 107:8-14.
11. Mbawuike IN, Lange AR, Couch RB: Diminished influenza A virus-specific
MHC class I-restricted cytotoxic T lymphocyte activity among elderly
persons. Viral Immunology 1993, 6:55-64.
12. Reis e Sousa C: Dendritic cells in a mature age. Nature Reviews in
Immunology 2007, 6:476-483.
13. Romero-Steiner S, Musher DM, Cetron MS, Pais LB, Groover JE, Fiore AE,
Plikaytis BD, Carlone GM: Reduction in functional antibody activity against
Streptococcus pneumoniae in vaccinated elderly individuals highly
correlates with decreased IgG antibody avidity. Clinical and Infectious
Disease 1999, 29:281-288.
14. Vallejo AN: Age-dependent alterations of the T cell repertoire and
functional diversity of T cells of the aged. Immunological Research 2007,
36:221-228.
15. Whitley RJ, Monto AS: Prevention and treatment of influenza in high-risk
groups: children, pregnant women, immunocompromised hosts, and
nursing home residents. Journal of Infectious Diseases 2006, 194(S2):
S133-S138.
16. Elliot A, Fleming D: Influenza and respiratory syncytial virus in the
elderly. Expert Review of Vaccines 2008, 7:249-258.
17. Cox NJ, Subbarao K: Influenza. The Lancet 1999, 354:1277-1282.
18. Wilson IA, Cox NJ: Structural basis of immune recognition of influenza
virus hemagglutinin. Annual Review of Immunology 1990, 8:737-771.
19. Gross PA, Hermogenes A, Sacks HS, Lau J, Levandowski RA: The efficacy of
influenza vaccine in elderly persons. A meta-analysis and review of the
literature. Annals of Internal Medicine 1995, 123:518-527.
20. Jefferson T, Rivetti D, Rudin M, Di Pietrantonj C, Demicheli V: Efficacy and
effectiveness of influenza vaccines in elderly people: a systematic
review. Lancet 2005, 366:1165-1174.
21. Goodwin K, Viboud C, Simonsen L: Antibody response to influenza
vaccination in the elderly: a quantitative review. Vaccine 2006,
24:1159-1169.
22. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE:
Vaccines for preventing influenza in the elderly. Cochrane Database of
Systematic Reviews 2010, 2(2):CD004876.
23. Jefferson T, Jones M, Doshi P, Del Mar C, Dooley L, Foxlee R:
Neuraminidase inhibitors for preventing and treating influenza in
healthy adults. Cochrane Database of Systematic Reviews, Issue 2, article
number CD001265 2010.
24. McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA: Influenza
(H5N1) with decreased oseltamivir sensitivity, Indonesia. Emerging
Infectious Diseases 2007, 13:1354-1357.
25. Monto A: Implications of antiviral resistance of influenza viruses. Clinical
Infectious Diseases 2009, 48:397-399.
26. Aoki FY, Boivin G, Roberts N: Influenza virus susceptibility and resistance
to oseltamivir. Antiviral Therapy 2007, 12:603-616.
27. Holland JJ: Defective viral genomes. In Virology. Volume 1.. 2 edition.
Edited by: Fields BN, Knipe DM. New York: Raven Press; 1990:151-165.
28. Holland JJ: Generation and replication of defective viral genomes. In
Virology.. 2 edition. Edited by: Fields BN, Knipe DM. New York: Raven Press;
1990:77-99.
29. Huang AS, Baltimore D: Defective viral particles and viral disease
processes. Nature (London) 1970, 226:325-327.
30. Nayak DP, Chambers TM, Akkina RM: Structure of defective-interfering
RNAs of influenza virus and their role in interference. In The Influenza
Viruses. Edited by: Krug RM. New York: Plenum Press; 1989:269-317.
31. Perrault J: Origin and replication of defective interfering particles. Current
Topics in Microbiology and Immunology 1981, 93:151-207.
32. von Magnus P: Incomplete forms of influenza virus. Advances in Virus
Research 1954, 21:59-79.
33. Nayak DP, Chambers TM, Akkina RK: Defective-interfering (DI) RNAs of
influenza viruses: origin, structure, expression and interference. Current
Topics in Microbiology and Immunology 1985, 114:103-151.
34. Jennings PA, Finch JT, Winter G, Robertson JS: Does the higher order of
the influenza virus ribonucleoprotein guide sequence rearrangements in
influenza viral RNA. Cell 1983, 34:619-627.
35. Duhaut SD, Dimmock NJ: Heterologous protection against a lethal
human H1N1 influenza virus infection of mice by a H3N8 equine
defective interfering virus: comparison of defective RNA sequences
isolated from the DI inoculum and mouse lung. Virology 1998,
248:241-253.
36. Dimmock NJ, Rainsford EW, Scott PD, Marriott AC: Influenza virus
protecting RNA: an effective prophylactic and therapeutic antiviral.
Journal of Virology 2008, 82:8570-8578.
37. Marriott AC, Dimmock NJ: Defective interfering viruses and their potential
as antiviral agents. Reviews in Medical Virology 2010, 20:51-62.
38. Toapanta FR, Ross TM: Impaired immune responses in the lungs of aged
mice following influenza infection. Respiratory Research 2009, 10:112.
39. Wen ZY, Ye L, Gao YL, Pan L, Dong K, Bu ZG, Compans RW, Yang CL:
Immunization by influenza virus-like particles protects aged mice
against lethal influenza virus challenge. Antiviral Research 2009,
84:215-224.
40. Dong L, Mori I, Hossain MJ, Kimura Y: The senescence-accelerated mouse
shows aging-related defects in cellular but not humoral imunity against
influenza virus. Journal of Infectious Diseases 2000, 182:391-396.
41. Dong L, Mori I, Hossain MJ, Liu B, Kimura Y: An immunostimulatory
oligodeooxynucleotide containing a cytidine-guanosine motif protects
senescence-accelerated mice from lethal influenza virus by augmenting
the T helper type 1 response. Journal of General Virology 2003,
84:1623-1628.
42. Effros RB, Walford RL: The immune response of aged mice to influenza:
diminished T-cell proliferation, interleukin 2 production and cytotoxicity.
Cellular Immunolology 1983, 81:298-305.
43. Po JL, Gardner EM, Anaraki F, Katsikis PD, Murasko DM: Age-associated
decrease in virus-specific CD8+ T lymphocytes during primary influenza
infection. Mechanisms of Ageing and Development 2002, 123:1167-1181.
44. Zheng B, Zhang Y, He H, Marinova E, Switzer K, Wansley D, Mbawuike I,
Han S: Rectification of age-associated deficiency in cytotoxic T cell
response to influenza A virus by immunization with immune complexes.
Journal of Immunology 2007, 179:6153-6159.
45. Easton AJ, Scott PD, Edworthy NL, Meng B, Marriott AC, Dimmock NJ: A
novel broad-spectrum treatment for respiratory virus infections:
influenza-based defective interfering virus provides protection against
pneumovirus infection in vivo. Vaccine 2011, 29:2777-2784.